|
a |
|
b/processing/MACCROBAT/20146086.ann |
|
|
1 |
T1 Age 2 13 54-year-old |
|
|
2 |
T2 Sex 14 19 woman |
|
|
3 |
T3 Disease_disorder 34 39 NSCLC |
|
|
4 |
E1 Disease_disorder:T3 |
|
|
5 |
T4 Detailed_description 25 33 stage IV |
|
|
6 |
R1 MODIFY Arg1:T4 Arg2:E1 |
|
|
7 |
T5 Medication 57 68 carboplatin |
|
|
8 |
E2 Medication:T5 |
|
|
9 |
T6 Medication 73 83 paclitaxel |
|
|
10 |
E3 Medication:T6 |
|
|
11 |
T8 Diagnostic_procedure 110 128 Molecular analysis |
|
|
12 |
E4 Diagnostic_procedure:T8 |
|
|
13 |
T9 Diagnostic_procedure 132 144 tumor tissue |
|
|
14 |
E5 Diagnostic_procedure:T9 |
|
|
15 |
R2 SUB_PROCEDURE Arg1:E5 Arg2:E4 |
|
|
16 |
T10 Detailed_description 149 160 unavailable |
|
|
17 |
R3 MODIFY Arg1:T10 Arg2:E4 |
|
|
18 |
T12 Personal_background 209 214 Asian |
|
|
19 |
T13 History 224 239 smoking history |
|
|
20 |
T14 Severity 216 223 minimal |
|
|
21 |
R4 MODIFY Arg1:T14 Arg2:T13 |
|
|
22 |
T16 Medication 387 396 erlotinib |
|
|
23 |
E7 Medication:T16 |
|
|
24 |
T17 Lab_value 398 404 150 mg |
|
|
25 |
R5 MODIFY Arg1:T17 Arg2:T15 |
|
|
26 |
T18 Detailed_description 362 370 standard |
|
|
27 |
R7 MODIFY Arg1:T18 Arg2:T15 |
|
|
28 |
R8 BEFORE Arg1:E1 Arg2:E2 |
|
|
29 |
* OVERLAP E2 E3 E4 |
|
|
30 |
T19 Coreference 410 421 her disease |
|
|
31 |
E9 Coreference:T19 |
|
|
32 |
T20 Date 433 458 Twenty-eight months later |
|
|
33 |
E10 Date:T20 |
|
|
34 |
T21 Medication 487 496 erlotinib |
|
|
35 |
E11 Medication:T21 |
|
|
36 |
T22 Coreference 517 524 disease |
|
|
37 |
E12 Coreference:T22 |
|
|
38 |
T23 Detailed_description 525 537 systemically |
|
|
39 |
T24 Sign_symptom 4114 4122 survived |
|
|
40 |
E13 Sign_symptom:T24 |
|
|
41 |
T25 Date 4123 4171 14 months following the diagnosis of CNS disease |
|
|
42 |
E14 Date:T25 |
|
|
43 |
T26 Disease_disorder 4160 4171 CNS disease |
|
|
44 |
E15 Disease_disorder:T26 |
|
|
45 |
* OVERLAP E13 E14 |
|
|
46 |
T27 Date 3959 3974 One month later |
|
|
47 |
E16 Date:T27 |
|
|
48 |
T28 Medication 4032 4041 cetixumab |
|
|
49 |
E17 Medication:T28 |
|
|
50 |
T29 Medication 4046 4055 erlotinib |
|
|
51 |
E18 Medication:T29 |
|
|
52 |
T30 Lab_value 4095 4101 100 mg |
|
|
53 |
T31 Dosage 4085 4093;4103 4108 low dose daily |
|
|
54 |
R13 MODIFY Arg1:T30 Arg2:T31 |
|
|
55 |
T33 Dosage 3933 3947 1500 mg weekly |
|
|
56 |
T35 Medication 3948 3957 erlotinib |
|
|
57 |
E19 Medication:T35 |
|
|
58 |
R14 MODIFY Arg1:T33 Arg2:E19 |
|
|
59 |
R16 MODIFY Arg1:T31 Arg2:E18 |
|
|
60 |
A3 TREND E18 DEC |
|
|
61 |
R18 BEFORE Arg1:E19 Arg2:E16 |
|
|
62 |
T36 Disease_disorder 3988 4010 intra-thoracic disease |
|
|
63 |
E20 Disease_disorder:T36 |
|
|
64 |
T37 Detailed_description 3976 3987 progressive |
|
|
65 |
R19 MODIFY Arg1:T37 Arg2:E20 |
|
|
66 |
* OVERLAP E16 E20 |
|
|
67 |
R20 BEFORE Arg1:E20 Arg2:E17 |
|
|
68 |
* OVERLAP E17 E18 |
|
|
69 |
R21 BEFORE Arg1:E18 Arg2:E13 |
|
|
70 |
T38 Diagnostic_procedure 256 265 histology |
|
|
71 |
E21 Diagnostic_procedure:T38 |
|
|
72 |
T39 Detailed_description 241 255 non-small cell |
|
|
73 |
R22 MODIFY Arg1:T39 Arg2:E21 |
|
|
74 |
T40 Coreference 277 288 her disease |
|
|
75 |
E22 Coreference:T40 |
|
|
76 |
R23 IDENTICAL Arg1:E22 Arg2:E1 |
|
|
77 |
A4 POLARITY E4 NEG |
|
|
78 |
T47 History 256 265 histology |
|
|
79 |
T48 Diagnostic_procedure 302 326 EGFR TKI sensitive cells |
|
|
80 |
E23 Diagnostic_procedure:T48 |
|
|
81 |
R24 MODIFY Arg1:E23 Arg2:E22 |
|
|
82 |
R25 BEFORE Arg1:E23 Arg2:E7 |
|
|
83 |
R26 IDENTICAL Arg1:E12 Arg2:E9 |
|
|
84 |
T53 Detailed_description 502 513 progression |
|
|
85 |
R27 MODIFY Arg1:T53 Arg2:E12 |
|
|
86 |
* OVERLAP E11 E12 |
|
|
87 |
T54 Medication 593 615 angiogenesis inhibitor |
|
|
88 |
E24 Medication:T54 |
|
|
89 |
T55 Detailed_description 580 592 experimental |
|
|
90 |
R28 MODIFY Arg1:T55 Arg2:E24 |
|
|
91 |
T56 Medication 631 641 pemetrexed |
|
|
92 |
E25 Medication:T56 |
|
|
93 |
T57 Coreference 654 677 standard dose erlotinib |
|
|
94 |
E26 Coreference:T57 |
|
|
95 |
* OVERLAP E25 E26 |
|
|
96 |
T60 Date 703 718 11 months later |
|
|
97 |
E27 Date:T60 |
|
|
98 |
T61 Coreference 720 731 her disease |
|
|
99 |
E28 Coreference:T61 |
|
|
100 |
R29 IDENTICAL Arg1:E28 Arg2:E12 |
|
|
101 |
T62 Detailed_description 738 748 progressed |
|
|
102 |
R30 MODIFY Arg1:T62 Arg2:E28 |
|
|
103 |
* OVERLAP E28 E27 E30 |
|
|
104 |
R31 BEFORE Arg1:E26 Arg2:E27 |
|
|
105 |
T67 Other_event 473 483 resistance |
|
|
106 |
E29 Other_event:T67 |
|
|
107 |
* OVERLAP E10 E29 |
|
|
108 |
R32 MODIFY Arg1:E11 Arg2:E29 |
|
|
109 |
R33 BEFORE Arg1:E12 Arg2:E24 |
|
|
110 |
R34 BEFORE Arg1:E24 Arg2:E25 |
|
|
111 |
T68 Diagnostic_procedure 773 779 biopsy |
|
|
112 |
E30 Diagnostic_procedure:T68 |
|
|
113 |
T69 Diagnostic_procedure 887 904 Direct sequencing |
|
|
114 |
E31 Diagnostic_procedure:T69 |
|
|
115 |
T70 Diagnostic_procedure 950 954 EGFR |
|
|
116 |
E32 Diagnostic_procedure:T70 |
|
|
117 |
T71 Detailed_description 933 946 kinase domain |
|
|
118 |
R35 MODIFY Arg1:T71 Arg2:E32 |
|
|
119 |
T72 Diagnostic_procedure 968 982 L858R mutation |
|
|
120 |
E33 Diagnostic_procedure:T72 |
|
|
121 |
R36 SUB_PROCEDURE Arg1:E33 Arg2:E32 |
|
|
122 |
R37 SUB_PROCEDURE Arg1:E32 Arg2:E31 |
|
|
123 |
T73 Diagnostic_procedure 1058 1072 T790M mutation |
|
|
124 |
E34 Diagnostic_procedure:T73 |
|
|
125 |
T74 Biological_structure 750 753 DNA |
|
|
126 |
R38 MODIFY Arg1:T74 Arg2:E30 |
|
|
127 |
T75 Disease_disorder 802 808 lesion |
|
|
128 |
E35 Disease_disorder:T75 |
|
|
129 |
T76 Biological_structure 797 801 lung |
|
|
130 |
T77 Detailed_description 785 796 progressing |
|
|
131 |
R39 MODIFY Arg1:T76 Arg2:E35 |
|
|
132 |
R40 MODIFY Arg1:T77 Arg2:E35 |
|
|
133 |
T78 Diagnostic_procedure 867 881 EGFR mutations |
|
|
134 |
E36 Diagnostic_procedure:T78 |
|
|
135 |
T79 Sign_symptom 1150 1159 headaches |
|
|
136 |
E37 Sign_symptom:T79 |
|
|
137 |
T80 Disease_disorder 1207 1217 metastases |
|
|
138 |
E38 Disease_disorder:T80 |
|
|
139 |
T81 Biological_structure 1203 1206 CNS |
|
|
140 |
R41 MODIFY Arg1:T81 Arg2:E38 |
|
|
141 |
A5 POLARITY E38 MAYBE_POS |
|
|
142 |
T82 Diagnostic_procedure 1235 1242 imaging |
|
|
143 |
E39 Diagnostic_procedure:T82 |
|
|
144 |
T83 Lab_value 1226 1234 negative |
|
|
145 |
R42 MODIFY Arg1:T83 Arg2:E39 |
|
|
146 |
A6 POLARITY E39 NEG |
|
|
147 |
T84 Detailed_description 908 919 exons 18–21 |
|
|
148 |
R43 MODIFY Arg1:T84 Arg2:T71 |
|
|
149 |
T85 Detailed_description 999 1019 EGFR TKI sensitivity |
|
|
150 |
R44 MODIFY Arg1:T85 Arg2:E33 |
|
|
151 |
T86 Detailed_description 1089 1117 acquired EGFR TKI resistance |
|
|
152 |
R45 MODIFY Arg1:T86 Arg2:E34 |
|
|
153 |
T87 Therapeutic_procedure 1270 1285 lumbar puncture |
|
|
154 |
E40 Therapeutic_procedure:T87 |
|
|
155 |
A7 POLARITY E40 NEG |
|
|
156 |
T88 Medication 1309 1321 temozolomide |
|
|
157 |
E41 Medication:T88 |
|
|
158 |
T89 Detailed_description 1301 1308 empiric |
|
|
159 |
R46 MODIFY Arg1:T89 Arg2:E41 |
|
|
160 |
R47 MODIFY Arg1:T23 Arg2:E12 |
|
|
161 |
R50 MODIFY Arg1:E35 Arg2:E30 |
|
|
162 |
T90 Detailed_description 1327 1340 standard dose |
|
|
163 |
T92 Medication 1341 1350 erlotinib |
|
|
164 |
E6 Medication:T92 |
|
|
165 |
T93 Dosage 1352 1364 150 mg daily |
|
|
166 |
T91 Disease_disorder 1379 1390 CNS disease |
|
|
167 |
E42 Disease_disorder:T91 |
|
|
168 |
A8 POLARITY E42 MAYBE_POS |
|
|
169 |
T94 Time 1396 1411 after one cycle |
|
|
170 |
E43 Time:T94 |
|
|
171 |
T95 Sign_symptom 1416 1425 headaches |
|
|
172 |
E44 Sign_symptom:T95 |
|
|
173 |
T96 Lab_value 1426 1434 worsened |
|
|
174 |
R51 MODIFY Arg1:T96 Arg2:E44 |
|
|
175 |
T97 Sign_symptom 1454 1460 nausea |
|
|
176 |
E45 Sign_symptom:T97 |
|
|
177 |
T98 Sign_symptom 1465 1473 vomiting |
|
|
178 |
E46 Sign_symptom:T98 |
|
|
179 |
T99 Disease_disorder 1489 1503 CNS metastases |
|
|
180 |
E47 Disease_disorder:T99 |
|
|
181 |
T100 Diagnostic_procedure 1527 1548 intracranial pressure |
|
|
182 |
E48 Diagnostic_procedure:T100 |
|
|
183 |
T101 Lab_value 1520 1526 raised |
|
|
184 |
R52 MODIFY Arg1:T101 Arg2:E48 |
|
|
185 |
T102 Diagnostic_procedure 1550 1576 Magnetic resonance imaging |
|
|
186 |
E49 Diagnostic_procedure:T102 |
|
|
187 |
T103 Diagnostic_procedure 1577 1582 (MRI) |
|
|
188 |
E50 Diagnostic_procedure:T103 |
|
|
189 |
R53 IDENTICAL Arg1:E50 Arg2:E49 |
|
|
190 |
T104 Biological_structure 1590 1595 brain |
|
|
191 |
T105 Diagnostic_procedure 1637 1649 CSF cytology |
|
|
192 |
E51 Diagnostic_procedure:T105 |
|
|
193 |
R54 MODIFY Arg1:T104 Arg2:E50 |
|
|
194 |
R55 SUB_PROCEDURE Arg1:E51 Arg2:E50 |
|
|
195 |
T106 Disease_disorder 1613 1615 LM |
|
|
196 |
E52 Disease_disorder:T106 |
|
|
197 |
T107 Biological_structure 1685 1688 DNA |
|
|
198 |
T108 Diagnostic_procedure 1673 1683 sequencing |
|
|
199 |
E53 Diagnostic_procedure:T108 |
|
|
200 |
T109 Detailed_description 1666 1672 direct |
|
|
201 |
R56 MODIFY Arg1:T109 Arg2:E53 |
|
|
202 |
T110 Diagnostic_procedure 1694 1703 CSF cells |
|
|
203 |
E54 Diagnostic_procedure:T110 |
|
|
204 |
T111 Diagnostic_procedure 1713 1718 L858R |
|
|
205 |
E55 Diagnostic_procedure:T111 |
|
|
206 |
T112 Diagnostic_procedure 1730 1750 EGFR TKI sensitivity |
|
|
207 |
E56 Diagnostic_procedure:T112 |
|
|
208 |
T113 Diagnostic_procedure 1783 1808 T790M resistance mutation |
|
|
209 |
E57 Diagnostic_procedure:T113 |
|
|
210 |
T114 Diagnostic_procedure 1850 1855 T790M |
|
|
211 |
E58 Diagnostic_procedure:T114 |
|
|
212 |
A9 POLARITY E58 NEG |
|
|
213 |
T115 Lab_value 1860 1868 negative |
|
|
214 |
R57 MODIFY Arg1:T115 Arg2:E58 |
|
|
215 |
A10 POLARITY E56 MAYBE_POS |
|
|
216 |
A11 POLARITY E57 MAYBE_NEG |
|
|
217 |
T116 Coreference 1872 1883 this sample |
|
|
218 |
E59 Coreference:T116 |
|
|
219 |
R58 IDENTICAL Arg1:E59 Arg2:E54 |
|
|
220 |
T117 Diagnostic_procedure 1948 1953 assay |
|
|
221 |
E60 Diagnostic_procedure:T117 |
|
|
222 |
T118 Lab_value 1900 1914 more sensitive |
|
|
223 |
T119 Detailed_description 1915 1937 fluorescence detection |
|
|
224 |
T120 Detailed_description 1938 1947 PCR-based |
|
|
225 |
R59 MODIFY Arg1:T120 Arg2:E60 |
|
|
226 |
R60 MODIFY Arg1:T119 Arg2:E60 |
|
|
227 |
R61 MODIFY Arg1:T118 Arg2:E60 |
|
|
228 |
T121 Diagnostic_procedure 1980 2024 PCR restriction fragment length polymorphism |
|
|
229 |
E61 Diagnostic_procedure:T121 |
|
|
230 |
T122 Coreference 2038 2068 the specific missense mutation |
|
|
231 |
E62 Coreference:T122 |
|
|
232 |
T123 Coreference 2120 2131 That result |
|
|
233 |
E63 Coreference:T123 |
|
|
234 |
A12 POLARITY E63 NEG |
|
|
235 |
T124 Lab_value 2141 2149 negative |
|
|
236 |
R62 MODIFY Arg1:T124 Arg2:E63 |
|
|
237 |
T125 Diagnostic_procedure 2163 2177 wild type peak |
|
|
238 |
E64 Diagnostic_procedure:T125 |
|
|
239 |
A13 POLARITY E64 POS |
|
|
240 |
R63 IDENTICAL Arg1:E63 Arg2:E60 |
|
|
241 |
R64 SUB_PROCEDURE Arg1:E62 Arg2:E61 |
|
|
242 |
R65 IDENTICAL Arg1:E62 Arg2:E57 |
|
|
243 |
T155 Diagnostic_procedure 3025 3049 Pharmacokinetic analysis |
|
|
244 |
E76 Diagnostic_procedure:T155 |
|
|
245 |
T156 Biological_structure 3053 3056 CSF |
|
|
246 |
R81 MODIFY Arg1:T156 Arg2:E76 |
|
|
247 |
T157 Subject 3062 3077 another patient |
|
|
248 |
T158 Disease_disorder 3089 3091 LM |
|
|
249 |
E77 Disease_disorder:T158 |
|
|
250 |
T159 Disease_disorder 3083 3088 NSCLC |
|
|
251 |
E78 Disease_disorder:T159 |
|
|
252 |
R82 MODIFY Arg1:E78 Arg2:E77 |
|
|
253 |
T160 Dosage 3117 3124;3135 3141 1500 mg weekly |
|
|
254 |
T162 Medication 3125 3134 erlotinib |
|
|
255 |
E79 Medication:T162 |
|
|
256 |
R88 MODIFY Arg1:T160 Arg2:E79 |
|
|
257 |
R90 MODIFY Arg1:T93 Arg2:T90 |
|
|
258 |
R91 MODIFY Arg1:T90 Arg2:E6 |
|
|
259 |
T165 Lab_value 3186 3195 11,300 nM |
|
|
260 |
T166 Diagnostic_procedure 3157 3182 peak plasma concentration |
|
|
261 |
E80 Diagnostic_procedure:T166 |
|
|
262 |
T169 Lab_value 3235 3241 130 nM |
|
|
263 |
T170 Diagnostic_procedure 3214 3231 CSF concentration |
|
|
264 |
E81 Diagnostic_procedure:T170 |
|
|
265 |
R75 MODIFY Arg1:T169 Arg2:E81 |
|
|
266 |
R92 MODIFY Arg1:T165 Arg2:E80 |
|
|
267 |
T172 Detailed_description 3333 3351 exceeding the IC50 |
|
|
268 |
R93 MODIFY Arg1:T172 Arg2:T169 |
|
|
269 |
T178 Dosage 3458 3474 high-dose weekly |
|
|
270 |
T179 Medication 3475 3484 erlotinib |
|
|
271 |
E87 Medication:T179 |
|
|
272 |
T180 Lab_value 3488 3495 1000 mg |
|
|
273 |
T181 Lab_value 3501 3508 1200 mg |
|
|
274 |
R96 MODIFY Arg1:T178 Arg2:E87 |
|
|
275 |
R98 MODIFY Arg1:T180 Arg2:T178 |
|
|
276 |
R99 MODIFY Arg1:T181 Arg2:T178 |
|
|
277 |
R100 MODIFY Arg1:T178 Arg2:E87 |
|
|
278 |
T182 Sign_symptom 3521 3527 nausea |
|
|
279 |
E88 Sign_symptom:T182 |
|
|
280 |
T183 Detailed_description 3510 3520 persistent |
|
|
281 |
R102 MODIFY Arg1:T183 Arg2:E88 |
|
|
282 |
T184 Diagnostic_procedure 3552 3576 Pharmacokinetic analysis |
|
|
283 |
E89 Diagnostic_procedure:T184 |
|
|
284 |
A15 POLARITY E89 NEG |
|
|
285 |
T186 Disease_disorder 3758 3771 hydrocephalus |
|
|
286 |
E91 Disease_disorder:T186 |
|
|
287 |
T187 Sign_symptom 3787 3795 symptoms |
|
|
288 |
E92 Sign_symptom:T187 |
|
|
289 |
T188 Detailed_description 3776 3786 persistent |
|
|
290 |
R104 MODIFY Arg1:T188 Arg2:E92 |
|
|
291 |
T189 Diagnostic_procedure 3819 3840 intracranial pressure |
|
|
292 |
E93 Diagnostic_procedure:T189 |
|
|
293 |
T190 Therapeutic_procedure 3850 3858 VP shunt |
|
|
294 |
E94 Therapeutic_procedure:T190 |
|
|
295 |
T191 Lab_value 3809 3818 increased |
|
|
296 |
R105 MODIFY Arg1:T191 Arg2:E93 |
|
|
297 |
T192 Therapeutic_procedure 3875 3892 radiation therapy |
|
|
298 |
E95 Therapeutic_procedure:T192 |
|
|
299 |
T193 Biological_structure 3863 3874 whole-brain |
|
|
300 |
R106 MODIFY Arg1:T193 Arg2:E95 |
|
|
301 |
T7 Detailed_description 84 108 without disease response |
|
|
302 |
R9 MODIFY Arg1:T7 Arg2:E2 |
|
|
303 |
R10 MODIFY Arg1:T7 Arg2:E3 |
|
|
304 |
A2 POLARITY E23 MAYBE_POS |
|
|
305 |
* OVERLAP E5 E23 |
|
|
306 |
R11 IDENTICAL Arg1:E9 Arg2:E22 |
|
|
307 |
R12 BEFORE Arg1:E7 Arg2:E9 |
|
|
308 |
T11 Detailed_description 422 431 responded |
|
|
309 |
R107 MODIFY Arg1:T11 Arg2:E9 |
|
|
310 |
R108 BEFORE Arg1:E9 Arg2:E10 |
|
|
311 |
#1 AnnotatorNotes E29 Not sure how to label drug resistance |
|
|
312 |
R109 SUB_PROCEDURE Arg1:E36 Arg2:E30 |
|
|
313 |
R110 SUB_PROCEDURE Arg1:E31 Arg2:E36 |
|
|
314 |
R111 SUB_PROCEDURE Arg1:E34 Arg2:E8 |
|
|
315 |
T41 Coreference 1033 1035 It |
|
|
316 |
E8 Coreference:T41 |
|
|
317 |
R112 IDENTICAL Arg1:E8 Arg2:E31 |
|
|
318 |
* OVERLAP E34 E37 E38 E39 E40 E41 E6 E42 |
|
|
319 |
R113 BEFORE Arg1:E42 Arg2:E43 |
|
|
320 |
* OVERLAP E43 E44 E45 E46 E47 |
|
|
321 |
A1 POLARITY E47 MAYBE_POS |
|
|
322 |
R114 MODIFY Arg1:E48 Arg2:E47 |
|
|
323 |
* OVERLAP E48 E49 |
|
|
324 |
R115 MODIFY Arg1:E52 Arg2:E50 |
|
|
325 |
R116 MODIFY Arg1:E52 Arg2:E51 |
|
|
326 |
* OVERLAP E51 E53 |
|
|
327 |
R117 MODIFY Arg1:T107 Arg2:E54 |
|
|
328 |
R118 SUB_PROCEDURE Arg1:E54 Arg2:E53 |
|
|
329 |
R119 SUB_PROCEDURE Arg1:E55 Arg2:E54 |
|
|
330 |
R120 SUB_PROCEDURE Arg1:E56 Arg2:E55 |
|
|
331 |
R121 SUB_PROCEDURE Arg1:E57 Arg2:E54 |
|
|
332 |
* OVERLAP E57 E58 E60 |
|
|
333 |
R122 SUB_PROCEDURE Arg1:E61 Arg2:E60 |
|
|
334 |
* OVERLAP E62 E63 |
|
|
335 |
R123 SUB_PROCEDURE Arg1:E64 Arg2:E63 |
|
|
336 |
R66 MODIFY Arg1:T157 Arg2:E76 |
|
|
337 |
R67 MODIFY Arg1:E77 Arg2:T157 |
|
|
338 |
* OVERLAP E77 E79 E80 E81 |
|
|
339 |
* OVERLAP E64 E76 |
|
|
340 |
R68 BEFORE Arg1:E81 Arg2:E87 |
|
|
341 |
* OVERLAP E87 E88 E89 |
|
|
342 |
T42 Date 3613 3626 After 1 month |
|
|
343 |
E65 Date:T42 |
|
|
344 |
R69 BEFORE Arg1:E89 Arg2:E65 |
|
|
345 |
T43 Diagnostic_procedure 3684 3687 MRI |
|
|
346 |
E66 Diagnostic_procedure:T43 |
|
|
347 |
T44 Biological_structure 3678 3683 brain |
|
|
348 |
R70 MODIFY Arg1:T44 Arg2:E66 |
|
|
349 |
T45 Date 3701 3715 after 2 months |
|
|
350 |
E67 Date:T45 |
|
|
351 |
T46 Biological_structure 3723 3735 cauda equina |
|
|
352 |
R71 BEFORE Arg1:E66 Arg2:E67 |
|
|
353 |
T49 Disease_disorder 3672 3674 LM |
|
|
354 |
E68 Disease_disorder:T49 |
|
|
355 |
T50 Diagnostic_procedure 3639 3668 partial radiographic response |
|
|
356 |
E69 Diagnostic_procedure:T50 |
|
|
357 |
R72 MODIFY Arg1:E68 Arg2:E69 |
|
|
358 |
* OVERLAP E65 E69 |
|
|
359 |
R73 SUB_PROCEDURE Arg1:E69 Arg2:E66 |
|
|
360 |
* OVERLAP E67 E91 E66 E92 E93 |
|
|
361 |
R74 MODIFY Arg1:T46 Arg2:E66 |
|
|
362 |
R76 BEFORE Arg1:E93 Arg2:E94 |
|
|
363 |
* OVERLAP E94 E95 |
|
|
364 |
R77 BEFORE Arg1:E95 Arg2:E19 |
|
|
365 |
T15 Dosage 371 383 daily dosing |
|
|
366 |
R6 MODIFY Arg1:T15 Arg2:E7 |
|
|
367 |
R48 IDENTICAL Arg1:E26 Arg2:E7 |